Laboratory of Therapeutic Proteins
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Synthesized peptides can slip into cells to block hard-to-target protein interactions
Synthesized peptides can slip into cells to block hard-to-target protein interactions Sadie Harley Scientific Editor Robert Egan Associate Editor Many diseases are driven by proteins interacting with each other inside cells. But blocking these interactions with drugs is difficult because typical "small-molecule" drugs often prove to be too small to grip the broad, flat surfaces involved in protein-protein interactions. On the other hand, peptides—short chains of amino acids—can cover larger...
Scientists found the hidden switch fueling alzheimer’s brain inflammation
Scientists found the hidden switch fueling alzheimer’s brain inflammation Scientists may have found a hidden Alzheimer’s “inflammation switch”—and turning it off protected brain connections in early studies. - Date: - May 31, 2026 - Source: - Scripps Research Institute - Summary: - Scientists at Scripps Research have uncovered a molecular “switch” that appears to fuel the damaging brain inflammation seen in Alzheimer’s disease. They found that a protein called STING becomes chemically...
Scientists unveil 'living bandage' that could dramatically speed wound healing
A new "living bandage" could soon revolutionize how doctors treat serious injuries by accelerating the healing process, according to new research reported by SWNS.The high-tech patch was developed by researchers at Rice University in Texas. It acts like an around-the-clock mini factory, continuously delivering healing proteins directly to different types of wounds, the same source noted. Caring for chronic wounds is often a challenge for doctors, as it's difficult to deliver steady,...
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch vehicles, and aerospace defense to the pharmaceutical sector. A growing number of companies are heading to lower Earth orbit to make medicines in microgravity. The range of commercial opportunities is expanding as foundational aerospace industries set the necessary infrastructure.
Some drugs 'fail' because of unrealistic testing conditions, scientists discover
Some drugs 'fail' because of unrealistic testing conditions, scientists discover Sadie Harley Scientific Editor Robert Egan Associate Editor A drug once dismissed as ineffective suddenly worked—when scientists tested it under more realistic conditions that mimic the human body. In this surprising new discovery, Northwestern University scientists uncovered a hidden rule of drug behavior. A medicine's effectiveness can change dramatically depending on the conditions inside our cells.
Fluorescent nanosensor detects key gut biomarker in minutes for faster testing
Fluorescent nanosensor detects key gut biomarker in minutes for faster testing Sadie Harley Scientific Editor Robert Egan Associate Editor A research collaboration has developed a novel fluorescent nanosensor capable of rapidly detecting indole-3-propionic acid (IPA), an emerging biomarker linked to gut health and disease. The breakthrough is described in the team's paper, "Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring," published in the journal...
A cheap arthritis drug shows promise treating RSV in early study
A cheap arthritis drug shows promise treating RSV in early study An arthritis drug reduces the amount of RSV in human respiratory cells, but experts say it's too early to say if it will actually treat the common infection. A cheap, widely available painkiller used to treat conditions like arthritis can significantly reduce RSV in the human respiratory tract, an early-stage laboratory study suggests. Respiratory syncytial virus (RSV) is the number one reason infants end up in the hospital in...
AI brews a caffeine-powered safety switch for future cell therapies
AI brews a caffeine-powered safety switch for future cell therapies Gaby Clark Scientific Editor Robert Egan Associate Editor For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines. A team at the Texas A&M Health Institute of Biosciences and Technology has developed an artificial intelligence-designed molecular switch that uses caffeine to rapidly separate engineered proteins...
When drug discovery fails: scientists share their frustrations with the process
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).